|
1）Johnson BE, Kris MG, Berry LD, et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). ASCO Annual Meeting. 2013; Abst. No. 8019
|
|
|
|
|
2）Mitsudomi T. Driver gene mutation and targeted therapy of lung cancer. Gan To Kagaku Ryoho. 2013; 40: 285-90
|
|
|
|
|
3）Cardarella S, Ortiz TM, Joshi VA, et al. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1767-74
|
|
|
|
|
4）Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012; 18: 375-7
|
|
|
|
|
|
5）Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-203
|
|
|
|
|
|
6）田澤義明, 西尾和人, 片山 稔, ほか.「個別化医療における薬剤および診断薬開発に向けての課題」第14回抗悪性腫瘍薬開発フォーラム記録. 腫瘍内科. 2013; 11: 610-62
|
|
|
|
|
|
7）Green RC, Berg JS, Grody WW. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15: 565-74
|
|
|
|
|